rethinkPeptides Search
Menu
Home / Research library
Study breakdown

GLP-1 Drugs May Shrink Coronary Artery Plaques in Diabetic Patients After Heart Attacks

RPEP-152152026Gitto, Mauro; Catapano, Federica; Francone, Marco; Mincione, Gianluca; Scialò, Vincenzo; Pivato, Carlo A; Lisi, Costanza; Regazzoli, Damiano; Cao, Davide; Fiorina, Roberta Maria; Petrelli, Alessandra; Bucciarelli, Loredana; Loretelli, Cristian; Condorelli, Gianluigi; Fiorina, Paolo; Stefanini, Giulio
evidence
The takeaway

GLP-1 receptor agonists were associated with coronary plaque regression in diabetic patients after acute coronary syndrome, potentially through anti-inflammatory and metabolic mechanisms beyond lipid lowering.

Plaque regression

GLP-1 drugs may actually shrink coronary artery plaques — reversing heart disease beyond what statins achieve alone

What the researchers found

GLP-1 RAs were associated with coronary plaque regression after ACS in diabetic patients, through anti-inflammatory, endothelial, and metabolic mechanisms complementary to statin-mediated lipid lowering.

Why it matters

Coronary plaque regression is the holy grail of cardiology — actually reversing heart disease rather than just slowing it. GLP-1 drugs may provide this benefit.

How the study worked

Review of clinical evidence on GLP-1 RA effects on coronary atherosclerosis progression and regression in diabetic ACS patients.

What this study cannot tell us

Evidence mostly from observational imaging studies. Randomized trials with intravascular imaging endpoints needed. Cannot separate weight loss effects from direct vascular effects.

How to read the evidence

Review of emerging imaging and clinical evidence. Promising but needs randomized imaging trials.

When this study was published

Published in 2025.

The bigger picture

If GLP-1 drugs can regress coronary plaques, they may fundamentally change cardiovascular disease management in diabetic patients from prevention to reversal.

Questions still open

  • Would dedicated imaging trials confirm GLP-1 plaque regression?
  • How much of the regression is due to weight loss vs direct vascular effects?
  • Should all diabetic ACS patients receive GLP-1 drugs?

Common questions

Can GLP-1 drugs reverse heart disease?
Emerging evidence suggests they may help shrink the plaques that cause heart attacks in diabetic patients. This goes beyond current treatments that mainly slow plaque growth.
Should heart attack patients take GLP-1 drugs?
For diabetic patients after a heart attack, the evidence increasingly supports adding GLP-1 drugs to standard treatment. They may help reverse plaque buildup through mechanisms different from statins.

Read the original research

GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes.

Acta diabetologica, 63(2), 179-191

View on PubMed ↗Publisher’s paper ↗

Citation

Gitto, Mauro; Catapano, Federica; Francone, Marco; Mincione, Gianluca; Scialò, Vincenzo; Pivato, Carlo A; Lisi, Costanza; Regazzoli, Damiano; Cao, Davide; Fiorina, Roberta Maria; Petrelli, Alessandra; Bucciarelli, Loredana; Loretelli, Cristian; Condorelli, Gianluigi; Fiorina, Paolo; Stefanini, Giulio. (2026). GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes.. Acta diabetologica, 63(2), 179-191. https://doi.org/10.1007/s00592-025-02606-z